Prostemix Commercializes World's First Probiotic Exosome Patent... Suppresses Cytokine Storm

New Immune-Boosting Product 'Cytovehicle' Launched
Maximizing Regeneration and Improvement of Damaged Skin and Hair Loss with Antibacterial and Anti-Inflammatory Functions
Accelerating Microbiome Drug Development with Advanced Exosome Technology

[Asia Economy Reporter Hyungsoo Park] Prostemics, a company specializing in stem cell and exosome research and development, will launch a new probiotic exosome-based skin immune-enhancing ampoule called ‘Cytovesicle’ on the 22nd.

Prostemics announced on the 15th that amid growing interest in immunity due to the novel coronavirus disease (COVID-19), it is releasing a new product containing probiotic exosomes derived from kefir grains, aiming to lead the microbiome market.

Cytovesicle is a skin immune-enhancing product containing high-purity, high-concentration probiotic exosomes, with strengths in maximizing skin regeneration by enhancing antibacterial and anti-inflammatory effects. It is explained to be effective in preventing the proliferation of harmful skin bacteria, alleviating inflammation, and improving damaged skin regeneration and hair loss.

Prostemics plans to launch the Cytovesicle product worldwide, including Japan. Utilizing the accumulated global network of its existing flagship product ‘AAPE,’ the company plans to continue multifaceted promotional strategies.

‘AAPE’ is an ampoule product by Prostemics for skin and hair loss regeneration treatment, which has been launched in over 30 countries worldwide over the past 14 years, with cumulative procedures exceeding 600,000 as of last year.

The core ingredient of Cytovesicle, probiotic exosomes derived from kefir grains, completed patent registration in Korea and the United States in March last year. This is the first in the world.

Based on advanced latest exosome production technology, Prostemics is building pipelines not only for treatments of Inflammatory Bowel Disease (IBD) but also microbiome-based anticancer therapies and atopic dermatitis treatments. The company is strengthening new drug development as a new business.

A company official stated, “We confirmed excellent immune regulatory functions and anti-inflammatory treatment efficacy, including suppression of cytokine storm (hyperimmune response) expression from probiotic exosomes,” adding, “We plan to apply for an Investigational New Drug (IND) clinical trial for the treatment of inflammatory bowel disease.”

Founded in 2005, Prostemics is a first-generation stem cell culture technology company that was the world’s first to register exosomes as raw materials with the Personal Care Products Council (PCPC) in the United States. Through its proprietary stem cell culture medium commercialization platform ‘Exoplant®,’ it possesses production capabilities and technology to culture, isolate, purify, and mass-produce high-quality exosomes.

This content was produced with the assistance of AI translation services.